Onset: 30–60 minutes (oral bark extract). Faster (15–30 min) with higher-potency 90%+ honokiol/magnolol extracts on empty stomach.

Peak: 1–3 hours post-dose. Effect is described as "shoulders drop, mind quiets, not sleepy yet but ready" — closer to L-theanine 400mg or low-dose magnesium-glycinate than to diphenhydramine or a benzo. No euphoria.

Plateau: 3–5 hours of clear anxiolytic effect at 200–500mg standardized. Effective half-life in humans is roughly 5–8 hours for honokiol and 4–6 hours for magnolol; total clinical effect typically wears off by morning.

Characteristic effects (dose-dependent):

• Low dose (100–200mg standardized): Mild anxiolysis without sedation. Some users dose this in PM-only "wind-down" stacks alongside L-theanine + glycine without affecting clarity.
• Moderate dose (200–500mg standardized, the Relora-trial range): Anxiolysis + mild sedation. The "right tool" for evenings where rumination or sympathetic dominance is the limiter on sleep onset.
• Higher dose (500–1000mg standardized, or 200mg+ of high-potency 90% extract): Frank sedation. Useful pre-sleep for heavier-stress nights. Some users describe a faint "warm, soft-edged" subjective quality — likely the CB1 piece.
• Cortisol blunting is mostly subjective via the "less wired in the evening" report — not acutely felt but trackable over 2–4 weeks via salivary cortisol (DUTCH test) or via subjective sleep-quality and HRV at night.

What it doesn't feel like:

• Not "stimulating" — anyone reporting energy/focus from magnolia is reporting de-stressed-baseline energy, not catecholaminergic push.
• Not "high" — no euphoria, no cognitive disinhibition, no impulse-control reduction at supplement doses (in contrast to alcohol, benzos, phenibut).
• Not a deep-sleep "knockout" — closer to slowing the runaway thoughts so natural sleep onset can happen.

Honest variability: ~10–15% of users describe paradoxical anxiety or stimulation rather than calm — the dopamine.club community reports flag "anxiety" as a side effect 16 times out of 239 reports. Etiology unclear; may relate to GABA-A α-subtype sensitivity heterogeneity. Trial dose at 200mg first, single dose, before scaling.

Pharmacological tolerance:

• Benzo-site GABA-A PAMs can induce receptor downregulation and tolerance in chronic high-dose models. Whether this translates to magnolia bark at supplement doses is unsettled.
• The Kuribara 1998 7-day dosing data showed increased efficacy after repeated dosing (anxiolysis at 0.2 mg/kg after 7 days vs. requiring 20 mg/kg acute), which is the opposite of classical benzo tolerance. Interpretation: either (a) magnolia bark builds steady-state levels and effect cumulates, or (b) the molecule doesn't drive the same receptor adaptations as diazepam at supplement doses.
• Community data: tolerance flagged in 9/239 reports — present but uncommon, not the dominant pattern.

Recommended cycling:

• Conservative: 6–8 weeks on, 1–2 weeks off. This is the default to apply to any GABAergic compound until human long-term data clarifies.
• Aggressive (if no benefit fade observed): Continuous use with monthly subjective reassessment. The Sarrica 2018 safety review (PMID 29925102) found no adverse events in trials up to 1 year, suggesting continuous use is at least safe; whether it's effective long-term is less clear.
• Discontinuation: No reports of clinically significant withdrawal at supplement doses. Some users report a few nights of suboptimal sleep when stopping abruptly after weeks of use — likely REM-rebound + loss of acute effect rather than withdrawal. Taper by every-other-night for 1 week if cautious.

Stack-rotation strategy (for Dylan): Rotate between magnolia bark (heavier-stress nights), lemon balm (lighter wind-down), and bare-stack baseline (no PM herbals) on a weekly or bi-weekly cycle. This addresses both tolerance and the "what's my actual baseline" calibration question.

Synergistic with

• L-theanine (200mg) — already in Dylan's stack. Different mechanism (presynaptic glutamate modulation, α-wave EEG). Pairs cleanly without overlap.
• Magnesium-glycinate (200–400mg elemental) — already in V4 stack. NMDA antagonism + GABA-A modulation. Synergistic for sleep-onset.
• Glycine (3g) — already in V4. Inhibitory neurotransmitter, mild thermal effect on sleep onset.
• Apigenin (50mg, from chamomile) — GABA-A benzo-site PAM (same mechanism site as magnolia). Some users find redundancy useful; risk of additive sedation at higher doses.
• Lemon balm (Melissa officinalis) 600mg — GABA transaminase inhibitor. Different mechanism. Good rotation partner.
• Ashwagandha (KSM-66, 600mg) — cortisol-blunting via separate mechanism (likely 5-HT2A modulation + GABA-mimetic). Synergistic for HPA-axis attenuation, dosed AM or PM.
• Phellodendron amurense (the other Relora ingredient) — co-formulated for cortisol synergy. The Relora data is the combination data; standalone magnolia data is more limited.

Avoid stacking with

• Benzodiazepines (alprazolam, diazepam, lorazepam, clonazepam): Additive GABA-A activity at the same binding site. Risk of excessive sedation and respiratory depression at higher doses. Avoid same-day combination.
• Z-drugs (zolpidem, zaleplon, eszopiclone): Same concern as benzos. Avoid.
• Phenibut: GABA-B agonism + magnolia's GABA-A activity — risk of compounded sedation and tolerance acceleration. (Phenibut is independently a SKIP-PERMANENT in this archetype.)
• Alcohol: Strongly additive CNS depression. Avoid same-night use.
• Opioids: Additive sedation + respiratory depression at higher doses. Avoid combination unless medically supervised.
• Other CB1 ligands (cannabis, THC products): Theoretical interaction via CB1 partial agonism. Untested but plausible — sedation could compound, and tolerance could cross-develop. Use caution.
• Kava (Piper methysticum): Both have GABA-A activity via distinct mechanisms; combined hepatic load is uncharacterized.

Neutral / safe co-administration

• All of Dylan's V4 day-stack supplements (citicoline, alpha-GPC, rhodiola, omega-3 DHA/EPA, vitamin D3/K2, NAC, beta-alanine, vitamin C, curcumin) — no interactions known.
• Modafinil at AM dosing (cleared by evening; mechanisms don't conflict).
• Creatine.
• Most peptides Dylan uses (BPC-157, TB-500, Selank, Semax, Adamax) — neutral interactions expected.

Magnolia's metabolic profile:

• Honokiol metabolism: Primarily via UGT-mediated glucuronidation (UGT1A8, UGT1A9, UGT2B7) and CYP3A4-mediated phase I oxidation. Low oral bioavailability (~5–10%) due to first-pass metabolism.
• Magnolol metabolism: Similar — glucuronidation + CYP3A4 oxidation. IC50 on CYP3A4 ≈ 56 μM (Tsai et al. 2014) — clinically achievable concentrations are below this IC50 at supplement doses, but flag for caution at higher doses or in CYP3A4 PM phenotypes.
• In vitro CYP inhibition (Tsai 2014): Honokiol inhibits CYP1A2, 2C8, 2C9, 2C19, 3A4 at varying potencies. Clinical relevance at supplement doses is unknown but theoretical.

Clinically significant interactions:

1. CNS depressants — ADDITIVE SEDATION

• Benzodiazepines, z-drugs, alcohol, opioids, phenibut, kava, baclofen, GHB-class compounds. Compounded GABA-A or general CNS depression. Avoid same-night combination.

2. CYP3A4 substrates — possibly increased levels (theoretical)

• At higher doses, magnolia may inhibit CYP3A4. Substrates to watch: statins (simvastatin, atorvastatin), some CCBs (amlodipine, diltiazem), cyclosporine, tacrolimus, midazolam, triazolam, certain SSRIs (citalopram via 2C19), buspirone, sildenafil. For Dylan (no current Rx CYP3A4 substrates), this is monitoring-only.

3. Hormonal contraceptives — minor, theoretical

• Honokiol's CYP3A4 inhibition could theoretically increase ethinyl estradiol exposure. Direction-of-effect is opposite to modafinil's induction. Not clinically reported. Partner-relevance only.

4. Anticoagulants (warfarin, apixaban, rivaroxaban) — monitor

• Magnolia has mild antiplatelet effects in vitro (Pyo et al. 2005). Risk of additive bleeding with anticoagulants. Discontinue 2 weeks pre-surgery.

5. Antidiabetic medications

• Magnolol shows mild hypoglycemic effects in animal models. Theoretical additive effect with insulin or sulfonylureas. Not relevant for Dylan.

6. CB1-acting compounds (cannabis, rimonabant-class)

• Theoretical interaction via shared CB1 receptor. Cannabis combination could amplify sedation; CB1 antagonist combination would blunt magnolia's anxiolytic effect.

7. SSRIs / SNRIs — minor

• Community-flagged "serotonin syndrome" topic (7 mentions in 239 reports) is likely coincidental — magnolia is not a serotonergic compound. Some users on SSRIs may experience additive sedation. Not a contraindication; monitor.

CYP3A4 / CYP3A5 polymorphism: ~10% of Caucasians are CYP3A5 expressers (rs776746). Magnolia metabolism via CYP3A4 is minor; impact on exposure is small. CYP3A5 expressers may clear magnolia slightly faster.

UGT1A9 / UGT2B7 polymorphism: Honokiol's primary clearance route is glucuronidation. UGT poor metabolizers (some populations) may have elevated honokiol exposure at standard doses. Practical implication: if Dylan turns out to have UGT slow-metabolizer variants on 23andMe, start at lower dose (100–200mg) and titrate up.

CYP2C19 status: Honokiol is a weak inhibitor in vitro. CYP2C19 PMs (~5% of Caucasians) on co-medications (omeprazole, citalopram, clopidogrel) may have slight exposure changes — not clinically significant at magnolia supplement doses.

GABA-A subunit polymorphism (GABRA1, GABRA2, GABRB): Variants in GABA-A subunit genes affect benzodiazepine response heterogeneity. The same likely applies to magnolia bark sensitivity. Paradoxical anxiety responders may carry specific α-subunit haplotypes — not yet validated in magnolia-specific studies.

Dylan's 23andMe data (June 2026 expected): UGT1A9 variants, CYP3A4/3A5 status, and any GABA-A subunit data are worth reviewing once results land — relevant to dose titration but not to whether to add magnolia at all.

Brand-by-brand notes:

• Nootropics Depot Honokiol 90% — gold standard for high-potency. 100–150mg cap = ~equivalent to 5g of standard 2% extract. Use at 100–200mg/day.
• Source Naturals Relora 250mg — the canonical Relora product. Matches the published trial format.
• Jarrow Formulas Magnolia Bark 200mg (2% honokiol) — clean, USP, easy retail availability.
• Life Extension Cortisol-Stress Balance — Relora + ashwagandha + magnolia + L-theanine combination. Worth considering for stack consolidation but layered formulations make titration harder.

For Dylan: Source Naturals Relora 250mg or Nootropics Depot Honokiol 90% (100mg cap), ~$15–25/month, slot into PM stack adjacent to existing magnesium-glycinate + L-theanine.

Baseline (before starting)

• Salivary cortisol AUC (DUTCH test or 4-point salivary panel) — Dylan's V4 stack already plans bloodwork for June 2026. Add a 4-point salivary cortisol (waking, +30min, noon, evening, pre-sleep) to characterize baseline diurnal slope. Magnolia's primary trackable effect is evening cortisol blunting.
• Subjective sleep-onset latency — 7-day VAS or sleep-tracker (Oura ring, Apple Health). Pre-magnolia baseline matters for measuring change.
• HRV at night (rMSSD) — Oura/Garmin/Whoop. Cortisol-blunting should correlate with higher rMSSD overnight.
• Subjective evening anxiety / rumination VAS (1–10 daily before bed for 7 days).
• ALT / AST — liver function baseline. Magnolia is well-tolerated but baseline matters if cycling years.
• Bedtime, total sleep time, sleep efficiency — Oura or equivalent tracker.

During use

• Weeks 1–2: paradoxical-anxiety + tolerance check — daily anxiety VAS, morning grogginess VAS. If anxiety rises or sedation persists into AM, drop dose.
• Weeks 2–4: sleep-onset latency improvement — should drop 10–20% from baseline if working. If no signal at 4 weeks, increase dose or discontinue.
• Weeks 4–8: cortisol re-test — repeat salivary cortisol panel; expect 10–20% evening cortisol reduction if responding (Talbott 2013 magnitudes).
• Monthly: subjective sleep quality, mood, training recovery scores.

Post-cycle (if cycled)

• After 1–2 weeks off, retest sleep onset and subjective anxiety. If symptoms return to baseline, magnolia is doing real work; resume. If symptoms stay improved, the effect was confounded with other interventions.